# Single Agent Abraxane as Second Line Therapy in Bladder Cancer

> **NCT00683059** · PHASE2 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 48 (actual)

## Conditions studied

- Transitional Cell Carcinoma

## Interventions

- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00683059
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683059, "Single Agent Abraxane as Second Line Therapy in Bladder Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00683059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*